Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00254436 · ClinicalTrials.gov registry record · Phase 3
A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
NCT00254436: Clinical Trial Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00254436 is a Phase 3 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00254436, a Phase 3 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
Study Summary
To demonstrate the effectiveness of epoetin alfa on reduction in red blood cell transfusions in gastric and rectal cancer patients undergoing preoperative chemoradiation therapy followed by surgery.
Interventions
- DRUG Procrit (epoetin alfa)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2001-10-31 |
| Est. Completion | 2004-06-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00254436
The ClinicalTrials.gov registry entry for NCT00254436 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Procrit (epoetin alfa) is the first listed.
NCT00254436 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00254436 about?
NCT00254436 is a clinical study titled "A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients". To demonstrate the effectiveness of epoetin alfa on reduction in red blood cell transfusions in gastric and rectal cancer patients undergoing preoperative chemoradiation therapy followed by surgery.
What is the current status of trial NCT00254436?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2001-10-31. Estimated completion is 2004-06-29.
What interventions are being tested in trial NCT00254436?
The interventions under investigation include: Procrit (epoetin alfa) (DRUG).
Who is sponsoring clinical trial NCT00254436?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.